Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Genmab ( (GMAB) ) is now available.
On February 20, 2026, Genmab A/S reported insider share transactions by a senior executive, complying with European market abuse regulations. The disclosure underscores the company’s adherence to transparency rules governing trading by managerial employees and their closely associated persons.
The filing details that Executive Vice President and Chief Financial Officer Anthony Pagano sold a total of 1,100 Genmab shares on February 19, 2026, on Nasdaq Copenhagen at an average price of DKK 1,810.10. While modest in size, the trade is formally reported under Article 19 of the Market Abuse Regulation, providing investors and regulators with timely visibility into management dealings in the stock.
The most recent analyst rating on (GMAB) stock is a Hold with a $34.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.
Genmab’s strong financial performance and positive earnings call sentiment are the primary drivers of its score. The company’s strategic initiatives and solid valuation further support its potential, despite some technical indicators suggesting caution.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab A/S is an international biotechnology company focused on developing innovative antibody medicines to treat cancer and other serious diseases. Founded in 1999 and headquartered in Copenhagen, Denmark, the company has built a portfolio that includes bispecific antibodies, antibody–drug conjugates, immune-modulating antibodies and other next-generation modalities, with eight approved antibody medicines and a strong late-stage clinical pipeline.
Average Trading Volume: 1,672,300
Technical Sentiment Signal: Buy
Current Market Cap: $17.69B
For a thorough assessment of GMAB stock, go to TipRanks’ Stock Analysis page.